Rallybio Corp RLYB
We take great care to ensure that the data presented and summarized in this overview for Rallybio Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RLYB
View all-
Viking Global Investors LP4.19MShares$3.82 Million0.02% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.64MShares$3.31 Million1.36% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$3.3 Million1.69% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$3 Million3.98% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$2.76 Million0.08% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA2.4MShares$2.19 Million2.22% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA1.91MShares$1.74 Million2.11% of portfolio
-
Abrdn PLC1.73MShares$1.57 Million0.0% of portfolio
-
Tekla Capital Management LLC1.73MShares$1.57 Million0.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA926KShares$842,2240.0% of portfolio
Latest Institutional Activity in RLYB
Top Purchases
Top Sells
About RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Insider Transactions at RLYB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2023
|
Jonathan I Lieber Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$25,000
$5.21 P/Share
|
|
Mar 07
2023
|
5 Am Partners V, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$800,000
$8.2 P/Share
|
|
Mar 07
2023
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
100,000
-4.03%
|
$800,000
$8.2 P/Share
|
|
Jun 03
2022
|
5 Am Opportunities I, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
150,000
-3.87%
|
$1,800,000
$12.5 P/Share
|
|
Jun 03
2022
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
150,000
-3.87%
|
$1,800,000
$12.5 P/Share
|
|
May 23
2022
|
5 Am Opportunities I, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
100,000
-2.51%
|
$1,300,000
$13.0 P/Share
|
|
May 23
2022
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
100,000
-2.51%
|
$1,300,000
$13.0 P/Share
|
|
Mar 21
2022
|
Jeffrey M Fryer Officer |
BUY
Open market or private purchase
|
Indirect |
3,000
+5.99%
|
$24,000
$8.04 P/Share
|
|
Feb 08
2022
|
Kush Parmar Director |
SELL
Open market or private sale
|
Indirect |
210,000
-5.01%
|
$2,730,000
$13.05 P/Share
|
|
Feb 08
2022
|
5 Am Opportunities I, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
210,000
-5.01%
|
$2,730,000
$13.05 P/Share
|
|
Jan 19
2022
|
Jeffrey M Fryer Officer |
BUY
Open market or private purchase
|
Indirect |
1,400
+3.08%
|
$11,200
$8.7 P/Share
|
|
Jan 13
2022
|
Stephen Uden Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.35%
|
$45,000
$9.34 P/Share
|
|
Jan 12
2022
|
Stephen Uden Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.7%
|
$50,000
$10.55 P/Share
|
|
Jan 11
2022
|
Martin Mackay Executive Chairman |
BUY
Open market or private purchase
|
Direct |
4,496
+1.57%
|
$44,960
$10.65 P/Share
|
|
Jan 10
2022
|
Martin Mackay Executive Chairman |
BUY
Open market or private purchase
|
Direct |
5,504
+1.94%
|
$55,040
$10.1 P/Share
|
|
Jan 07
2022
|
Jeffrey M Fryer Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+9.98%
|
$90,000
$9.21 P/Share
|
|
Aug 02
2021
|
5 Am Opportunities I, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
615,384
+30.44%
|
$7,999,992
$13.0 P/Share
|
|
Aug 02
2021
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
1,694,388
+50.0%
|
-
|
|
Aug 02
2021
|
Timothy M Shannon Director |
BUY
Open market or private purchase
|
Indirect |
76,923
+3.09%
|
$999,999
$13.0 P/Share
|
|
Aug 02
2021
|
Ronald Hunt Director |
BUY
Open market or private purchase
|
Indirect |
307,692
+6.47%
|
$3,999,996
$13.0 P/Share
|